These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

647 related articles for article (PubMed ID: 11709562)

  • 1. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.
    Bécouarn Y; Gamelin E; Coudert B; Négrier S; Pierga JY; Raoul JL; Provençal J; Rixe O; Krisch C; Germa C; Bekradda M; Mignard D; Mousseau M
    J Clin Oncol; 2001 Nov; 19(22):4195-201. PubMed ID: 11709562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
    Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
    J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
    Martinez J; Martin C; Chacon M; Korbenfeld E; Bella S; Senna S; Richardet E; Coppola F; Bas C; Hidalgo J; Escobar E; Reale M; Smilovich AM; Wasserman E
    Am J Clin Oncol; 2006 Feb; 29(1):45-51. PubMed ID: 16462502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan.
    Tai CJ; Liu JH; Chen WS; Lin JK; Wang WS; Yen CC; Chiou TJ; Chen PM
    Jpn J Clin Oncol; 2003 Mar; 33(3):136-40. PubMed ID: 12672791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
    Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
    Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.
    Fischer von Weikersthal L; Schalhorn A; Stauch M; Quietzsch D; Maubach PA; Lambertz H; Oruzio D; Schlag R; Weigang-Köhler K; Vehling-Kaiser U; Schulze M; Truckenbrodt J; Goebeler M; Mittermüller J; Bosse D; Szukics B; Grundeis M; Zwingers T; Giessen C; Heinemann V
    Eur J Cancer; 2011 Jan; 47(2):206-14. PubMed ID: 20971632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients.
    Zori Comba A; Blajman C; Richardet E; Bella S; Vilanova M; Cóppola F; Van Kooten M; Rodger J; Giglio R; Balbiani L; Perazzo F; Montiel M; Chacón M; Pujol F; Mickiewicz E; Cazap E; Recondo G; Lastiri F; Simon J; Wasserman E; Schmilovich A
    Eur J Cancer; 2001 May; 37(8):1006-13. PubMed ID: 11334726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
    Ferrari V; Valcamonico F; Amoroso V; Simoncini E; Vassalli L; Marpicati P; Rangoni G; Grisanti S; Pasinetti N; Marini G
    Oncology; 2005; 69(4):283-9. PubMed ID: 16282707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
    Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer.
    Bouzid K; Khalfallah S; Tujakowski J; Piko B; Purkalne G; Plate S; Padrik P; Serafy M; Pshevloutsky EM; Boussard B;
    Ann Oncol; 2003 Jul; 14(7):1106-14. PubMed ID: 12853354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
    Masi G; Allegrini G; Cupini S; Marcucci L; Cerri E; Brunetti I; Fontana E; Ricci S; Andreuccetti M; Falcone A
    Ann Oncol; 2004 Dec; 15(12):1766-72. PubMed ID: 15550581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
    Delaunoit T; Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Findlay BP; Thomas SP; Salim M; Schaefer PL; Stella PJ; Green E; Mailliard JA
    Cancer; 2004 Nov; 101(10):2170-6. PubMed ID: 15470715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer.
    Bécouarn Y; Senesse P; Thézenas S; Boucher E; Adenis A; Cany L; Jacob JH; Cvitkovic F; Montoto-Grillot C; Ychou M;
    Ann Oncol; 2007 Dec; 18(12):2000-5. PubMed ID: 17785765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients.
    Bajetta E; Beretta E; Di Bartolomeo M; Cortinovis D; Ferrario E; Dognini G; Toffolatti L; Buzzoni R
    Oncology; 2004; 66(2):132-7. PubMed ID: 15138365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
    Souglakos J; Mavroudis D; Kakolyris S; Kourousis Ch; Vardakis N; Androulakis N; Agelaki S; Kalbakis K; Tsetis D; Athanasiadis N; Samonis G; Georgoulias V
    J Clin Oncol; 2002 Jun; 20(11):2651-7. PubMed ID: 12039926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.
    Ychou M; Conroy T; Seitz JF; Gourgou S; Hua A; Mery-Mignard D; Kramar A
    Ann Oncol; 2003 Mar; 14(3):481-9. PubMed ID: 12598357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.
    Comella P; Casaretti R; De Vita F; Avallone A; Orditura M; Petrillo A; Gravina A; Faranda A; Comis S; Comella G; Catalano G
    Ann Oncol; 1999 Aug; 10(8):915-21. PubMed ID: 10509152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
    André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
    J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
    Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
    Comella P; Casaretti R; De Rosa V; Avallone A; Izzo F; Fiore F; Lapenta L; Comella G
    Ann Oncol; 2002 Dec; 13(12):1874-81. PubMed ID: 12453855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.